New hope for tough blood cancers: first human trial of MGD024 begins

NCT ID NCT05362773

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 26 times

Summary

This early-stage study tests a new drug called MGD024 in about 130 adults with certain blood cancers (like leukemia or lymphoma) that did not get better with standard treatments or came back. The main goal is to find a safe dose and understand side effects. Participants receive the drug for up to one year, and doctors will monitor how their cancer responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Colorado Blood Cancer Network

    RECRUITING

    Denver, Colorado, 80218, United States

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

  • Duke University Medical Center

    COMPLETED

    Durham, North Carolina, 27710, United States

  • START - Midwest

    RECRUITING

    Grand Rapids, Michigan, 49503, United States

  • South Austin Medical Center

    RECRUITING

    Austin, Texas, 78704, United States

  • University of Maryland, Greenbaum Comprehensive Cancer Center

    RECRUITING

    Baltimore, Maryland, 21201, United States

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.